Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co and TetraLogic in Keytruda combo deal

This article was originally published in Scrip

Executive Summary

Merck & Co and TetraLogic are to collaborate on a Phase I trial testing Merck's anti-PD-1 therapy Keytruda (pembrolizumab) with TetraLogic's SMAC-mimetic in patients with relapsed or refractory solid tumors. The deal builds on the growing trend to combine agents that act in different ways help the body's immune system to fight against cancer - a Phase II study combining Bristol-Myers Squibb's Yervoy (ipilimumab) with Opdivo (nivolumab) has just shown highly promising results in melanoma albeit with some side-effect problems. TetraLogic says its birinapant (TL32711) is a bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system's ability to kill abnormal cells via an extracellular TNF signal. Like Opdivo, Merck’s Keytruda is one of a number of agents targeting the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. Under the terms of the agreement, TetraLogic and Merck will collaborate on an initial Phase I dose-escalation study of the combination. TetraLogic will sponsor and fund the study and Merck will provide Keytruda. Results from the study will be used to determine the path for further clinical development of the combination.

You may also be interested in...



Urovant’s Vibegron Flops In IBS Study

Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Catabasis’s Future In Doubt After DMD Phase III Failure

Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel